Mithril
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 2
- Anthropic’s biomedicine strategy targets closed-loop drug discovery
A 36Kr review examines Anthropic’s biomedicine push, including Claude Science, the Model Hardware Standard for laboratory equipment, protein-design agents, wet-lab partnerships, and the Mithril and Coefficient Bio acquisitions. The review says Anthropic is using Claude to orchestrate molecular-design models such as BoltzGen and is building a “pipeline-in-a-person,” while wet-lab validation remains a constraint. It characterizes biomedicine as Anthropic’s next concentrated investment focus after coding and says the strategy is more focused than OpenAI’s broader life-science activities, though that comparison is editorial judgment.
36氪 人工智能 · 🔥 0 - Anthropic expands AI drug development and acquires Mithril
Anthropic detailed early-stage drug-development work with six partners and said it had acquired Mithril, a one-person company focused on muscular dystrophy. The company said AI could speed drug development beyond common uses such as proposing initial designs for new molecules. The announcement did not name the six partners or provide independent results from the work.
Techmeme · 🔥 0
Experience and discussion from the community
Share my Mithril experienceAsk about Mithril
Nobody has shared their experience with Mithril yet.